PROGNOSTIC VALUE OF pSTAT3 EXPRESSION IN DIFFUSIVE B-LARGE CELL LYMPHOMA IN THE RUSSIAN PATIENT SAMPLE
Elena Viktorovna VANEEVA, Vitaly Anatolyevich ROSIN, Dmitry Andreevich DYAKONOV, SvetlanaValeryevna SAMARINA, Andrey Valentinovich RYLOV
Kirov Research Institute of Hematology and Blood Transfusion of FMBA of Russia
Keywords: диффузная В-крупноклеточная лимфома, pSTAT3, экспрессия, выживаемость, GCB, non-GCB, IPI, diffuse large B-cell lymphoma, pSTAT3, expression, survival, GCB, non-GCB, IPI
Abstract
The aim of the study was to
evaluate the prognostic value of pSTAT3 expression in diffuse B-large
cell lymphoma (DLBCL) in a Russian sample of patients. Material and
methods. Retrospectively, the results of an examination of 50 patients
with newly diagnosed DLBCL in the period from 2014 to 2017 were
evaluated. Using immunohistochemical and morphometric methods, the
relative number of tumor cells expressing pSTAT3 was determined. The
relationship of various levels of marker expression with clinical and
laboratory parameters was analyzed, and long-term results of patient
therapy were evaluated. Results and discussion. The overexpression of
pSTAT3 protein is associated with a non-GCB subtype of the disease, an
advanced stage, the patients of 60 years and older age, as well as with a
lower frequency of achieving complete remissions with DLBCL. Patients
with a high degree of marker expression in tumor cells had lower rates
of overall (OS) and progressive survival (PFS). It was revealed that the
marker under study has good predictive ability, but is not an
independent prognosis factor for DLBCL. Conclusions. The level of
expression of pSTAT3 is an informative factor that allows predicting the
response to standard therapy for diffuse B-large cell lymphoma. The
indicated marker may be useful for identifying patients who need
individualization of therapeutic tactics for this disease.
|